Ficlatuzumab

Ficlatuzumab (AV-299) is a monoclonal antibody developed by AVEO Pharmaceuticals. The sponsor describes its target as HGF (hepatocyte growth factor), which OnCo does not yet have a target page for. The sponsor states: A humanized hepatocyte growth factor (HGF) inhibitory IgG1 monoclonal antibody that blocks HGF signalling, distinct from EGFR-targeted agents such as cetuximab. ClinicalTrials.gov describes the intervention as: Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06064877 (A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma), in head and neck squamous cell carcinoma. The largest, NCT06064877, plans to enrol 410 participants with primary completion expected 2027-08. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.